

Supplementary

Table S1 Primer sequences of the mRNA used in this study

mRNA	Primer sequences
cGAS	Forward: ACATGGCGGCTATCCTTCTCT Reverse: GGGTTCTGGGTACATACGTGAAA
STING	Forward: CCAGAGCACACTCTCCGGTA Reverse: CGCATTGGGAGGGAGTAGTA
GAPDH	Forward: GCACCGTCAAGGCTGAGAAC Reverse: TGGTGAAGACGCCAGTGGAA
MST1	Forward: GGAGACGGTACAGCTGAGGA Reverse: CAACAATCTGGCCGGTCTCT
FOXO1	Forward: TCGTCATAATCTGTCCTACACA Reverse: CGGCTTCGGCTTAGCAAA
ISD	Forward: TACAGATCTACTAGTGATCTATGACTGATCTGT ACATGATCTACA Reverse: TGTAGATCATGTACAGATCAGTCATAGATCACT AGTAGATCTGTA

cGAS, cyclic GMP-AMP synthase; STING, stimulator of interferon genes; MST1, mammalian sterile 20-like kinase 1; LATS1, large tumor suppressor kinase 1; YAP, Yes-associated protein; FOXO1, forkhead box1.

Table S2 Demographic and clinical features of patients with active RA

Demographic and clinical features	Values
Age, years (mean ± SD)	54.73±7.14
Female, n (%)	16 (80)
Male, n (%)	4 (20)
Disease duration, years (mean ± SD)	6.03±7.36
Rheumatoid factor-positive, n (%)	19 (95)
Anti-CCP positive, n (%)	17 (85)
DAS28 (CRP) (mean ± SD)	5.57±1.46
Previous medications, n (%)	
Prednisone (<10 mg/d)	8 (40)
Methotrexate	6 (30)
Leflunomide	1 (5)
Sulfasalazine	1(5)
Hydroxychloroquine	4 (20)

Table S3 shRNA target sequences

shRNA	Sequences
shcGAS-1	CAACTACGACTAAAGCCATT
shcGAS-2	GATGCTGTCAAAGTTAGGA
shcGAS-3	CGTGAAGATTTCTGCACCTAA
shSTING-1	CTGCTCGTAGCGCCGGGCCTT
shSTING-2	CAGCATTACAACAACCTGCTA
shSTING-3	GACCGGTGACCATGCTGGCAT

shRNA, short hairpin RNA.

Table S4 Sequences of siRNA

siRNA	Sequences
sicGAS-1	GTAAGGAATTCTGACAAA
sicGAS-2	CTAGCAACTTAATTGACAA
sicGAS-3	GGCTATCCTTCTCTCACAT
siSTING-1	GATGGGTTTACAGCAACA
siSTING-2	CTGGCATGGTCATATTACA
siSTING-3	GGATTCGAACTTACAATCA
siMST1-1	GGCAGCGTATACAAAGCTA
siMST1-2	CAAGCGGAATACAGTGATA
siMST1-3	GGTAGCAGGTCAACTTACA
siFOXO1-1	GAGGTATGAGTCAGTATAA
siFOXO1-2	GCCCTCGAACTAGCTAAA
siFOXO1-3	TTCGGAATGACCTCATGGAA

siRNA, small interfering RNA.